首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   240031篇
  免费   17798篇
  国内免费   5105篇
耳鼻咽喉   1514篇
儿科学   4412篇
妇产科学   3908篇
基础医学   26735篇
口腔科学   3436篇
临床医学   20273篇
内科学   38742篇
皮肤病学   2334篇
神经病学   13279篇
特种医学   10141篇
外国民族医学   4篇
外科学   19774篇
综合类   35652篇
一般理论   8篇
预防医学   17932篇
眼科学   2901篇
药学   32658篇
  157篇
中国医学   15680篇
肿瘤学   13394篇
  2023年   2912篇
  2022年   4308篇
  2021年   7779篇
  2020年   8965篇
  2019年   10270篇
  2018年   7625篇
  2017年   8414篇
  2016年   8291篇
  2015年   7816篇
  2014年   11056篇
  2013年   15941篇
  2012年   12588篇
  2011年   14654篇
  2010年   10121篇
  2009年   10163篇
  2008年   11535篇
  2007年   12604篇
  2006年   11745篇
  2005年   10680篇
  2004年   9120篇
  2003年   8145篇
  2002年   6409篇
  2001年   5941篇
  2000年   4948篇
  1999年   4176篇
  1998年   3218篇
  1997年   3298篇
  1996年   2938篇
  1995年   2872篇
  1994年   2725篇
  1993年   2184篇
  1992年   2048篇
  1991年   1874篇
  1990年   1637篇
  1989年   1350篇
  1988年   1314篇
  1987年   1183篇
  1986年   1072篇
  1985年   1543篇
  1984年   1260篇
  1983年   852篇
  1982年   976篇
  1981年   810篇
  1980年   787篇
  1979年   600篇
  1978年   393篇
  1977年   349篇
  1976年   312篇
  1975年   216篇
  1974年   170篇
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
1.
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data.  相似文献   
2.
3.
4.
5.
6.
7.
8.
9.
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment.  相似文献   
10.
Adiponectin is the major adipocytes-secreted protein involved in obesity-related breast cancer growth and progression. We proved that adiponectin promotes proliferation in ERα-positive breast cancer cells, through ERα transactivation and the recruitment of LKB1 as ERα-coactivator. Here, we showed that adiponectin-mediated ERα transactivation enhances E-cadherin expression. Thus, we investigated the molecular mechanism through which ERα/LKB1 complex may modulate the expression of E-cadherin, influencing tumor growth, progression and distant metastasis. We demonstrated that adiponectin increases E-cadherin expression in ERα-positive 2D and higher extent in 3D cultures. This occurs through a direct activation of E-cadherin gene promoter by ERα/LKB1-complex. The impact of E-cadherin on ERα-positive breast cancer cell proliferation comes from the evidence that in the presence of E-cadherin siRNA the proliferative effects of adiponectin is no longer noticeable. Since E-cadherin connects cell polarity and growth, we investigated if the adiponectin-enhanced E-cadherin expression could influence the localization of proteins cooperating in cell polarity, such as LKB1 and Cdc42. Surprisingly, immunofluorescence showed that, in adiponectin-treated MCF-7 cells, LKB1 and Cdc42 mostly colocalize in the nucleus, impairing their cytosolic cooperation in maintaining cell polarity. The orthotopic implantation of MCF-7 cells revealed an enhanced E-cadherin-mediated breast cancer growth induced by adiponectin. Moreover, tail vein injection of MCF-7 cells showed a higher metastatic burden in the lungs of mice receiving adiponectin-treated cells compared to control. From these findings it emerges that adiponectin treatment enhances E-cadherin expression, alters cell polarity and stimulates ERα-positive breast cancer cell growth in vitro and in vivo, sustaining higher distant metastatic burden.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号